title: Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study.
abstract: OBJECTIVE
  To compare the efficacy of two early cessation protocols of triptorelin treatment in controlled ovarian hyperstimulation with the conventional long protocol in in vitro fertilization/intracytoplasmic sperm injection.
  
  
  METHODS
  A double-blind, randomized, multicenter study.
  
  
  METHODS
  Three Dutch hospitals.
  
  
  METHODS
  One hundred seventy-eight women randomized to one of three treatment groups at the start of stimulation.
  
  
  METHODS
  Midluteally started triptorelin administration was continued until the first day of hMG treatment (group S), or up to and including the fourth day of hMG treatment (group M) or the day of hCG injection (group L).
  
  
  METHODS
  Occurrence of a premature LH surge.
  
  
  RESULTS
  One premature LH surge was observed in group M but not in groups S and L. Both early cessation protocols (S and M) are at least as effective as the long protocol (L) with regard to the number of oocytes (11.1 and 10.3 vs. 9.3), number of embryos (7.3 and 6.5 vs. 5.5), and ongoing pregnancy rate (28% and 24% vs. 21%).
  
  
  CONCLUSIONS
  Early cessation of triptorelin on day 1 of hMG treatment in a midluteally started IVF protocol is as effective as the traditional long protocol in preventing a premature LH surge and results in similar fertility effects.
authors.affiliation: University Medical Center Groningen, PO Box 30.001, 0700 RB Groningen, The Netherlands. a.h.m.simons@og.umcg.nl
authors.forename: Arnold H M
authors.initials: AH
authors.lastname: Simons
authors.forename: Henny J M
authors.initials: HJ
authors.lastname: Roelofs
authors.forename: Alex P E
authors.initials: AP
authors.lastname: Schmoutziguer
authors.forename: Brigitte J
authors.initials: BJ
authors.lastname: Roozenburg
authors.forename: Eefje P
authors.initials: EP
authors.lastname: van't Hof-van den Brink
authors.forename: Simon A
authors.initials: SA
authors.lastname: Schoonderwoerd
mesh_terms: D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005307:Fertilization in Vitro; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008596:Menotropins / Q000008:administration & dosage; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D020554:Sperm Injections, Intracytoplasmic; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D005300:Fertility Agents, Female; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D008596:Menotropins; D007986:Luteinizing Hormone